JPWO2019223733A5 - - Google Patents

Info

Publication number

JPWO2019223733A5

JPWO2019223733A5 JP2020565492A JP2020565492A JPWO2019223733A5 JP WO2019223733 A5 JPWO2019223733 A5 JP WO2019223733A5 JP 2020565492 A JP2020565492 A JP 2020565492A JP 2020565492 A JP2020565492 A JP 2020565492A JP WO2019223733 A5 JPWO2019223733 A5 JP WO2019223733A5

Authority

JP

Japan

Prior art keywords

seq

chain variable

variable region

antigen

heavy chain

Prior art date

2022-05-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 claims 12
• 102000036639 antigens Human genes 0.000 claims 12
• 108091007433 antigens Proteins 0.000 claims 12
• 239000012634 fragment Substances 0.000 claims 12
• 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 8
• 125000003275 alpha amino acid group Chemical group 0.000 claims 8
• 102000050320 human TNFRSF4 Human genes 0.000 claims 8
• 239000008194 pharmaceutical composition Substances 0.000 claims 7
• 229930012538 Paclitaxel Natural products 0.000 claims 3
• 125000000539 amino acid group Chemical group 0.000 claims 3
• 239000003814 drug Substances 0.000 claims 3
• 229960001592 paclitaxel Drugs 0.000 claims 3
• 238000006467 substitution reaction Methods 0.000 claims 3
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
• 229940124597 therapeutic agent Drugs 0.000 claims 3
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 2
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
• 229960004942 lenalidomide Drugs 0.000 claims 2
• 206010006187 Breast cancer Diseases 0.000 claims 1
• 208000026310 Breast neoplasm Diseases 0.000 claims 1
• 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
• 206010025323 Lymphomas Diseases 0.000 claims 1
• 206010027406 Mesothelioma Diseases 0.000 claims 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
• 206010033128 Ovarian cancer Diseases 0.000 claims 1
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
• 206010038389 Renal cancer Diseases 0.000 claims 1
• 206010039491 Sarcoma Diseases 0.000 claims 1
• 208000000453 Skin Neoplasms Diseases 0.000 claims 1
• 206010041067 Small cell lung cancer Diseases 0.000 claims 1
• 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
• 239000000556 agonist Substances 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 claims 1
• 229960004562 carboplatin Drugs 0.000 claims 1
• 190000008236 carboplatin Chemical compound 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 229960004316 cisplatin Drugs 0.000 claims 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
• 229960003668 docetaxel Drugs 0.000 claims 1
• 229960004679 doxorubicin Drugs 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 230000000694 effects Effects 0.000 claims 1
• 230000033581 fucosylation Effects 0.000 claims 1
• 206010017758 gastric cancer Diseases 0.000 claims 1
• 230000013595 glycosylation Effects 0.000 claims 1
• 238000006206 glycosylation reaction Methods 0.000 claims 1
• 201000010536 head and neck cancer Diseases 0.000 claims 1
• 208000014829 head and neck neoplasm Diseases 0.000 claims 1
• 229960004768 irinotecan Drugs 0.000 claims 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
• 201000010982 kidney cancer Diseases 0.000 claims 1
• 208000032839 leukemia Diseases 0.000 claims 1
• 201000007270 liver cancer Diseases 0.000 claims 1
• 208000014018 liver neoplasm Diseases 0.000 claims 1
• 201000000050 myeloid neoplasm Diseases 0.000 claims 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
• 201000000849 skin cancer Diseases 0.000 claims 1
• 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
• 201000011549 stomach cancer Diseases 0.000 claims 1
• 229960000303 topotecan Drugs 0.000 claims 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1